Novel chemotherapy using histone deacetylase inhibitors in cervical cancer

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 3, 2011, Pages 575-580

  Takai, Noriyuki ^a   Kira, Naoko ^a   Ishii, Terukazu ^a   Nishida, Masakazu ^a   Nasu, Kaei ^a   Narahara, Hisashi ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Cell cycle; Cervical cancer; Histone deacetylase inhibitor

Indexed keywords

EID: 79958861740     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Banuelos CA, Banáth JP, MacPhail SH, et al (2007). Radiosensitization by the histone deacetylase inhibitor PCI-24781. Clin Cancer Res, 13, 6816-26.
2. Blaheta RA, Nau H, Michaelis M, et al (2002). Valproate and valproate-analogues: potent tools to fight against cancer. Curr Medic Chem, 9, 1417-33.
3. Bolden JE, Peart MJ, Johnstone RW (2006). Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov, 5, 769-84.
4. Borutinskaite VV, Navakauskiene R, Magnusson KE (2006). Retinoic acid and histone deacetylase inhibitor BML-210 inhibit proliferation of human cervical cancer HeLa cells. Annal NY Acad Sci, 1091, 346-55.
5. Camacho LH, Olson J, Tong WP, et al (2007). Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest New Drugs, 25, 131-8.
6. Candido EPM, Reeves R, Davie JR (1978). Sodium butyrate inhibits histone deacetylation in cultured cells. Cell, 14, 105-13.
7. Chapman A, Keane PE, Meldrum BS, et al (1982). Mechanism of anticonvulsant action of valproate. Prog Neurobiol, 19, 315-59.
8. Chávez-Blanco A, Segura-Pacheco B, Pérez-Cárdenas E, et al (2005). Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. a phase I study. Mol Cancer, 4, 22.
9. Chávez-Blanco A, Perez-Plasencia C, Pérez-Cárdenas E, et al (2006). Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int, 6.??
10. Chung YL, Wang AJ, Yao LF (2004). Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: implications for increasing therapeutic gain in cancer radiotherapy. Mol Cancer Ther, 3, 317-25.
11. Darkin-Rattray SJ, Gurnett AM, Myers RW, et al (1996). Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc Natl Acad Sci USA, 93, 13143-7.
12. Darvas K, Rosenberger S, Brenner D, et al (2010). Histone deacetylase inhibitor-induced sensitization to TNFalpha/TRAIL-mediated apoptosis in cervical carcinoma cells is dependent on HPV oncogene expression. Int J Cancer, 127, 1384-92.
13. Decrion-Barthod AZ, Bosset M, Plissonnier ML, et al (2010). Sodium butyrate with UCN-01 has marked antitumour activity against cervical cancer cells. Anticancer Res, 30, 4049-61.
14. Finnin MS, Donigian JR, Cohen A, et al (1999). Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature, 401, 188-93.
15. Finzer P, Kuntzen C, Soto U, et al (2001). Inhibitors of histone deacetylase arrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression. Oncogene, 20, 4768-76.
16. Finzer P, Stöhr M, Seibert N, et al (2003). Phenylbutyrate inhibits growth of cervical carcinoma cells independent of HPV type and copy number. J Cancer Res Clin Oncol, 129, 107-13.
17. Gui CY, Ngo L, Xu WS, et al (2004). Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA, 101, 1241-6.
18. Haberland M, Montgomery RL, Olson EN (2009). The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet, 10, 32-42.
19. Han JW, Ahn SH, Park SH, et al (2000). Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res, 60, 6068-74.
20. Jenuwein T, Allis CD (2001). Translating the histone code. Science, 293, 1074-80.
21. Jung M, Brosch G, Kölle D, et al (1999). Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J Medic Chem, 42, 4669-79.
22. Lee BI, Park SH, Kim JW, et al (2001). MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells. Cancer Res, 61, 931-4.
23. Lin Z, Bazzaro M, Wang MC, et al (2009). Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. Clin Cancer Res, 15, 570-7.
24. Luczak MW, Agodzinski PP (2008). Apicidin down-regulates human papillomavirus type 16 E6 and E7 transcripts and proteins in SiHa cervical cancer cells. Cancer Lett, 272, 53-60.
25. Marchion D, Münster P (2007). Development of histone deacetylase inhibitors for cancer treatment. Expert Rev Anticancer Ther, 7, 583-98.
26. Modesitt SC, Sill M, Hoffman JS, et al (2008). A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol, 109, 182-6.
27. Munster PN, Marchion DC, Bicaku E, et al (2005). Phase I trial of the histone deacetylase inhibitor, valproic acid and the topoisomerase II inhibitor, epirubicin: a clinical and translational study. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings, 23, abstract no. 3084.
28. Park JK, Cho CH, Ramachandran S, et al (2006). Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3-kinase inhibition in the human cervical cancer cell-line. Cancer Res Treat, 38, 112-7.
29. Phiel CJ, Zhang F, Huang EY, et al (2001). Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem, 276, 36734-41.
30. Piekarz R, Bates S (2004). A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Design, 10, 2289-98.
31. Pisani P, Bray F, Parkin DM (2002). Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer, 97, 72-81.
32. Rosato RR, Almenara JA, Grant S (2003). The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1. Cancer Res, 63, 3637-45.
33. Ruefli AA, Ausserlechner MJ, Bernhard D, et al (2001). The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA, 98, 10833-8.
34. Ryan QC, Headlee D, Acharya M, et al (2005). Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol, 23, 3912-22.
35. Saito A, Yamashita T, Mariko Y, et al (1999). A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA, 96, 4592-7.
36. Sami S, Höti N, Xu HM, et al (2008). Valproic acid inhibits the growth of cervical cancer both in vitro and in vivo. J Biochem, 144, 357-62.
37. Sandor V, Robbins AR, Robey R, et al (2000). FR901228 causes mitotic arrest but does not alter microtubule polymerization. Anti-Cancer Drugs, 11, 445-54.
38. Strahl BD, Allis CD (2000). The language of covalent histone modifications. Nature, 403, 41-5.
39. Suzuki T, Ando T, Tsuchiya K, et al (1999). Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J Medic Chem, 42, 3001-3.
40. Takai N, Kawamata N, Gui D, et al (2004). Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer, 101, 2760-70.
41. Takai N, Ueda T, Nishida M, et al (2006a). Anticancer activity of MS-275, a novel histone deacetylase inhibitor, against human endometrial cancer cells. Anticancer Res, 26, 939-45.
42. Takai N, Ueda T, Nishida M, et ak (2006b). M344 is a novel synthesized histone deacetylase inhibitor that induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial cancer and ovarian cancer cells. Gynecol Oncol, 101, 108-13.
43. Takai N, Koeffler HP, Narahara H (2007a). Histone deacetylase inhibitors induce growth inhibition, cell cycle arrest and apoptosis in human cervical cancer cells. In 'New Research on Cervical Cancer', Eds Rolland GZ. Nova Science Publishers Inc., Hauppauge, NY, USA. pp 175-88.
44. Takai N, Narahara H (2007b). Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis. Curr Med Chem, 14, 2548-53.
45. Takai N, Narahara H (2010a). Histone deacetylase inhibitor therapy in epithelial ovarian cancer. J Oncol, ??.
46. Takai N, Narahara H (2010b). Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer. Obstet Gynecol Int, ??.
47. Terao Y, Nishida J, Horiuchi S, et al (2001). Sodium butyrate induces growth arrest and senescence-like phenotypes in gynecologic cancer cells. Int J Cancer, 94, 257-67.
48. Tsuji N, Kobayashi M, Nagashima K (1976). A new antifungal antibiotic, trichostatin. J Antibiot, 29, 1-6.
49. Tsuji N, Kobayashi M (1978). Trichostatin C, a glucopyranosyl hydroxamate. J Antibiot, 31, 939-44.
50. Ueda T, Takai N, Nishida M, et al (2007). Apicidin, a novel histone deacetylase inhibitor, has profound anti-growth activity in human endometrial and ovarian cancer cells. Int J Mol Med, 19, 301-8.
51. Van Lint C, Emiliani S, Verdin E (1996). The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expression, 5, 245-53.
52. Warrell Jr RP, He LZ, Richon V, et al (1998). Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst, 90, 1621-5.
53. Xu W, Ngo L, Perez G, et al (2006). Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci USA, 103, 15540-5.
54. Zhang Y, Jung M, Dritschilo A, et al (2004). Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat Res, 161, 667-74.